Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

16

Revenue 2017

Shire

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.

Shire

Deal Watch October 2018

Takeda, whose $62B acquisition of Shire is meeting some resistance at home, is rumoured to be considering the sale of some Shire products as and when the acquisition is closed (expected

Boston Scientific makes $4.2bn play for UK’s BTG

Boston Scientific makes $4.2bn play for UK’s BTG Its buyout is another reminder that the UK hasn't produced a 'big biotech' to rival Amgen or Genentech, nor even a mid-sized specialist pharma company since Shire's reached

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Heggie has lots of experience in the rare disease field, having served in senior roles at Shire, as a board member at Sobi and as CEO of German rare disease biotech

Shire’s angioedema drug Takhzyro recommended in Europe

Shire’s angioedema drug Takhzyro recommended in Europe The European Medicines Agency's CHMP committee has recommended Shire’s Takhzyro (lanadelumab), a new rare disease treatment which has blockbuster potential. ... Approved in the US in August, the drug is important for Shire, which is in the midst of a

Roche gets wider approval for haemophilia drug Hemlibra

Roche gets wider approval for haemophilia drug Hemlibra The broader indication means that Hemlibra can now challenge the entire range of factor VIII drugs in the marketplace – both short-acting and newer long-acting versions such as Shire’s

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics